Lipocine shareholders approve reduction in authorized shares from 200M to 75M

Lipocine Inc.

Authorized common stock reduced from 200M to 75M shares; Certificate of Amendment filed June 4, 2025.
All six director nominees elected: Dr. Mahesh V. Patel, Jeffrey A. Fink, John W. Higuchi, Dr. Jill M. Jene, Dr. Richard Dana Ono, Dr. Spyros Papapetropoulos.
Tanner LLC ratified as independent auditor for FY 2025 with 2,817,444 votes for, 86,618 against.
Non-binding advisory vote on executive compensation passed: 926,497 for, 121,032 against.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Lipocine Inc.: Reduction of authorized common stock from 200,000,000 to 75,000,000 shares via amendment to Amended and Restated Certificate of Incorporation (effective 2025-06-04).

Change: charter amendment
Effective: 2025-06-04

Exact text from the filing

On June 4, 2025, the Company filed the Amendment with the Secretary of State of the State of Delaware.

View on SEC.gov

Browse all governance changes →

Lipocine Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-013603

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.